Tiratricol: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Brian Blank (talk | contribs)
nocaptcha
2,344 edits
No edit summary
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Tiratricol": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{drugbox
 
| IUPAC_name       = 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]<br>acetic acid
{{Drugbox
| image             = Tiratricol.jpg
| Verifiedfields = changed
| CAS_number        = 51-24-1
| verifiedrevid = 470610738
| ATC_prefix        = H03
| IUPAC_name = [4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
| ATC_suffix        = AA04
| image = Tiratricol.svg
| ATC_supplemental  = {{ATC|D11|AX08}}
| width = 240
| PubChem          = 5803
| image2 = Tiratricol_3D_ball.png
| DrugBank          =
| alt2 = Ball-and-stick model of the tiratricol molecule
| C = 14 | H = 9 | I = 3 | O = 4
<!--Clinical data-->
| molecular_weight  = 621.932 g/mol
| tradename =
| synonyms          = 3,3',5-triiodothyroacetic acid<br>TRIAC
| Drugs.com = {{drugs.com|international|tiratricol}}
| bioavailability  =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| protein_bound    = Presumed high
| pregnancy_US = <!-- A / B            / C / D / X -->
| metabolism        = [[Liver|Hepatic]] [[glucuronidation]]
| pregnancy_category =   
| elimination_half-life =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| excretion        = Biliary
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| pregnancy_AU     = <!-- A / B1 / B2 / B3 / C / D / X -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| pregnancy_US     = <!-- A / B            / C / D / X -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| pregnancy_category=   
| legal_status =
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| routes_of_administration =
| legal_CA         = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
 
| legal_UK         = <!-- GSL        / P      / POM / CD / Class A, B, C -->
<!--Pharmacokinetic data-->
| legal_US         = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| bioavailability = 
| legal_status     =  
| protein_bound = Presumed high
| routes_of_administration =  
| metabolism = [[Liver|Hepatic]] [[glucuronidation]]
| elimination_half-life = 
| excretion = Biliary
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 51-24-1
| ATC_prefix = H03
| ATC_suffix = AA04
| ATC_supplemental =  {{ATC|D11|AX08}}
| PubChem = 5803
| IUPHAR_ligand = 2637
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB03604
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5598
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 29OQ9EU4R1
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07214
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 41632
 
<!--Chemical data-->
| C=14 | H=9 | I=3 | O=4
| molecular_weight = 621.932 g/mol
| smiles = Ic2cc(Oc1c(I)cc(cc1I)CC(=O)O)ccc2O
| InChI = 1/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
| InChIKey = UOWZUVNAGUAEQC-UHFFFAOYAM
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UOWZUVNAGUAEQC-UHFFFAOYSA-N
| synonyms = 3,3',5-triiodothyroacetic acid<br>TRIAC
}}
}}
              __NOTOC__
{{SI}}
{{SI}}
__NOTOC__
{{CMG}}
{{Editor Help}}
==Overview==


==Overview==
'''Tiratricol''' (also known as '''TRIAC''') is a [[thyroid hormone]] [[analog (chemistry)|analogue]]. It is indicated in the management of [[thyroid hormone resistance|thyroid hormone resistance syndrome]]<ref>{{cite journal |author=Carvalho GA, Ramos HE |title=[Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=/S0004-27302004000100010}} {{PDFlink|[http://www.scielo.br/pdf/abem/v48n1/19522.pdf Free full text]|95.3&nbsp;[[Kibibyte|KiB]]<!-- application/pdf, 97642 bytes -->}}</ref> and is used, in combination with [[levothyroxine]], to suppress [[thyroid-stimulating hormone]] production in patients with [[thyroid cancer]].


Tiratricol has also been widely marketed, under various trade names, as a [[weight loss]] aid. In 1999 and 2000, the United States [[Food and Drug Administration]] and [[Health Canada]] both issued warnings to the public regarding the use of [[dietary supplement]]s containing tiratricol.<ref>{{cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21 2000 | accessdate = | publisher = U.S. [[Food and Drug Administration]]}}</ref><ref>{{cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2 1999 | accessdate = | publisher = Health Canada}}</ref>
'''Tiratricol''' (also known as '''TRIAC''' or triiodothyroacetic acid) is a [[thyroid hormone]] [[analog (chemistry)|analogue]].
 
==Uses==
It is indicated in the management of [[thyroid hormone resistance|thyroid hormone resistance syndrome]]<ref>{{cite journal |author=Carvalho GA, Ramos HE |title=[Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=10.1590/S0004-27302004000100010}} {{PDFlink|[http://www.scielo.br/pdf/abem/v48n1/19522.pdf Free full text]|95.3&nbsp;[[Kibibyte|KiB]]<!-- application/pdf, 97642 bytes -->}}</ref> and is used, in combination with [[levothyroxine]], to suppress [[thyroid-stimulating hormone]] production in patients with [[thyroid cancer]].
 
It has been investigated for use in reducing [[goiter]].<ref name="pmid14602763">{{cite journal |author=Brenta G, Schnitman M, Fretes O, ''et al.'' |title=Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=11 |pages=5287–92 |date=November 2003 |pmid=14602763 |doi= 10.1210/jc.2003-030095|url=http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=14602763}}</ref>
 
It has also shown some effectiveness in reducing the atrophy caused when using [[corticosteroid]]s.<ref name="pmid17123343">{{cite journal |author=Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J |title=Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans |journal=Thyroid |volume=16 |issue=11 |pages=1157–62 |date=November 2006 |pmid=17123343 |doi=10.1089/thy.2006.16.1157}}</ref>
 
Tiratricol has also been widely marketed, under various trade names, as a [[weight loss]] aid. In 1999 and 2000, the United States [[Food and Drug Administration]] and [[Health Canada]] both issued warnings to the public regarding the use of [[dietary supplement]]s containing tiratricol.<ref>{{cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21, 2000 | accessdate = 2007-08-08 | publisher = U.S. [[Food and Drug Administration]]}}</ref><ref>{{cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2, 1999 | accessdate = 2007-08-08 | publisher = [[Health Canada]]}}</ref>


==Legal status==
==Legal status==
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.<ref>{{cite web | url = http://www.endocrino.org.br/noticia_g_exibe.php?id=9 | title = Anvisa suspende Tiratricol | language = Portuguese | date = | accessdate = | publisher = Brazilian Society of Endocrinology and Metabolism}}</ref>
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in [[Brazil]], but its marketing authorization was suspended in 2003, effectively prohibiting its sale.<ref>{{cite web | url = http://www.endocrino.org.br/noticia_g_exibe.php?id=9 | title = Anvisa suspende Tiratricol | language = Portuguese | date = | accessdate = 2007-08-08 | publisher = Brazilian Society of Endocrinology and Metabolism |archiveurl = http://web.archive.org/web/20071009062707/http://www.endocrino.org.br/noticia_g_exibe.php?id=9 <!-- Bot retrieved archive --> |archivedate = 2007-10-09}}</ref> Tiratricol is still available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer.<ref>Laboratoires DB PHARMA: [http://www.db-pharma.com/fiche.cfm?id=24 Teatrois] information</ref> It is available as an [[orphan drug]] to be prescribed by registered specialists in Europe.


==References==
==References==
{{Reflist}}
{{Reflist|2}}


{{Other dermatological preparations}}
{{Other dermatological preparations}}
{{Thyroid therapy}}
{{Thyroid therapy}}
{{SIB}}
 
[[Category:Orphan drugs]]
[[Category:Orphan drugs]]
[[Category:Endocrinology]]
[[Category:Organoiodides]]
{{WikiDoc Help Menu}}
[[Category:Phenols]]
{{WikiDoc Sources}}
[[Category:Phenol ethers]]
[[Category:Drug]]

Latest revision as of 17:18, 20 August 2015

Tiratricol
Ball-and-stick model of the tiratricol molecule
Clinical data
Synonyms3,3',5-triiodothyroacetic acid
TRIAC
AHFS/Drugs.comInternational Drug Names
ATC code
Pharmacokinetic data
Protein bindingPresumed high
MetabolismHepatic glucuronidation
ExcretionBiliary
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H9I3O4
Molar mass621.932 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Tiratricol

Articles

Most recent articles on Tiratricol

Most cited articles on Tiratricol

Review articles on Tiratricol

Articles on Tiratricol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tiratricol

Images of Tiratricol

Photos of Tiratricol

Podcasts & MP3s on Tiratricol

Videos on Tiratricol

Evidence Based Medicine

Cochrane Collaboration on Tiratricol

Bandolier on Tiratricol

TRIP on Tiratricol

Clinical Trials

Ongoing Trials on Tiratricol at Clinical Trials.gov

Trial results on Tiratricol

Clinical Trials on Tiratricol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tiratricol

NICE Guidance on Tiratricol

NHS PRODIGY Guidance

FDA on Tiratricol

CDC on Tiratricol

Books

Books on Tiratricol

News

Tiratricol in the news

Be alerted to news on Tiratricol

News trends on Tiratricol

Commentary

Blogs on Tiratricol

Definitions

Definitions of Tiratricol

Patient Resources / Community

Patient resources on Tiratricol

Discussion groups on Tiratricol

Patient Handouts on Tiratricol

Directions to Hospitals Treating Tiratricol

Risk calculators and risk factors for Tiratricol

Healthcare Provider Resources

Symptoms of Tiratricol

Causes & Risk Factors for Tiratricol

Diagnostic studies for Tiratricol

Treatment of Tiratricol

Continuing Medical Education (CME)

CME Programs on Tiratricol

International

Tiratricol en Espanol

Tiratricol en Francais

Business

Tiratricol in the Marketplace

Patents on Tiratricol

Experimental / Informatics

List of terms related to Tiratricol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.

Uses

It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

It has been investigated for use in reducing goiter.[2]

It has also shown some effectiveness in reducing the atrophy caused when using corticosteroids.[3]

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[4][5]

Legal status

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[6] Tiratricol is still available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer.[7] It is available as an orphan drug to be prescribed by registered specialists in Europe.

References

  1. ↑ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese). 48 (1): 83–92. doi:10.1590/S0004-27302004000100010. PMID 15611821. Template:PDFlink
  2. ↑ Brenta G, Schnitman M, Fretes O; et al. (November 2003). "Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid". J. Clin. Endocrinol. Metab. 88 (11): 5287–92. doi:10.1210/jc.2003-030095. PMID 14602763.
  3. ↑ Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J (November 2006). "Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans". Thyroid. 16 (11): 1157–62. doi:10.1089/thy.2006.16.1157. PMID 17123343.
  4. ↑ "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21, 2000. Retrieved 2007-08-08.
  5. ↑ "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2, 1999. Retrieved 2007-08-08.
  6. ↑ "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism. Archived from the original on 2007-10-09. Retrieved 2007-08-08.
  7. ↑ Laboratoires DB PHARMA: Teatrois information

Template:Thyroid therapy

Retrieved from "https://www.wikidoc.org/index.php?title=Tiratricol&oldid=1137706"